Jacky Scanlan-Dyas is a Corporate partner in the firm's Tokyo office with extensive experience spanning 3 continents and 20 years of cross-border corporate transactions. Her areas of experience include mergers & acquisitions, joint ventures, restructurings, complex commercial agreements and private equity deals. She knows how to get deals done in Japan, having lived there for over 10 years.
Jacky has extensive international experience which enables her to navigate cross-cultural issues that arise in multi-jurisdictional transactions, and also advise clients on Japan out-bound transactions. She focuses on cross-border corporate transactions such as M&A, Joint Ventures and Restructurings both for Japanese clients investing outside of Japan and for non-Japanese clients investing into Japan.
Jacky also advises on general corporate and commercial matters in connection with all aspects of the company lifecycle. These range from company establishment, governance, investment and winding up to purchase and sale arrangements, distribution as well as franchise agreements.
Jacky is recognised as an up and coming practitioner by various publications including Chambers Asia Pacific. Jacky speaks English and an intermediate level of Japanese.
After graduating with honours in law and a bachelor of arts in Japanese from Canterbury University in New Zealand she commenced her career with New Zealand's pre-eminent law firm. Like many other Kiwis she wanted to explore the world and so in 1998 she left New Zealand and has spent her time since then in London, New York and Tokyo.
'Jacky Scanlan-Dyas concentrates on cross-border M&A and is recognised as a lawyer whose attention to detail is just right', Chambers Asia-Pacific
“A truly first-class professional whose candour, industry and superb commercial advice put her skills much in demand. She played a key role in the majority of the team’s most significant recent deals”
Jacky regularly advises Japanese trading houses on their investments and joint ventures outside of Japan
Jacky advised a listed U.S. pharmaceuticals company on the disposal of its Japan-based manufacturing facilities.
Advising a Japanese trading house on numerous sale and purchase agreements in connection with the establishment of a new commodities based business line.
Latest thinking and events
15 July 2016